Home / Business and Economy / Pfizer India Profits Soar 19.4% in Q2 2025 on Robust Sales
Pfizer India Profits Soar 19.4% in Q2 2025 on Robust Sales
12 Nov
Summary
- Pfizer India's Q2 2025 net profit rises 19.4% to ₹189 crore
- Company receives approval to sell leased assets, booking ₹172.81 crore gain
- Shareholders approve ₹165 per share dividend, including special payouts
On November 12, 2025, Pfizer India announced a robust financial performance for the September quarter (Q2 FY26). The company reported a 19.4% year-on-year rise in net profit to ₹189 crore, compared to ₹158 crore in the same period last year.
The strong results were driven by steady demand across Pfizer's key therapeutic segments, leading to a 9.1% increase in revenue from operations to ₹642.3 crore. The company also highlighted improved operational efficiency during the quarter.
Additionally, Pfizer disclosed that it had received approvals from the Maharashtra Industrial Development Corporation (MIDC) for the assignment and sale of its leased land and building assets in the previous quarter, resulting in a net gain of ₹172.81 crore, which was recorded as an exceptional item.
Shareholders of Pfizer India also approved a total dividend payout of ₹165 per equity share (1,650% of face value ₹10) at the company's annual general meeting on July 21, 2025. This included a final dividend of ₹35, a special dividend of ₹100 marking Pfizer's 75th year in India, and an additional ₹30 per share special dividend linked to the MIDC asset sale gain. The dividend was distributed on July 25, 2025.
Shares of Pfizer India ended 0.48% higher at ₹5,021.00 on the NSE on November 12, 2025.
